| Terminated | Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Impr Acute Respiratory Distress Syndrome, Coronavirus, Hypoxic Respiratory Failure | Phase 2 | 2020-07-15 |
| Terminated | Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) in PAH Subjects Following Completion of Study Pulmonary Arterial Hypertension | Phase 2 | 2019-04-10 |
| Terminated | Phase 2 Study to Assess Safety, Tolerability and Efficacy of Once Weekly SC Pemziviptadil (PB1046) in Subjects Pulmonary Arterial Hypertension | Phase 2 | 2018-07-15 |
| Completed | A Study to Assess the Safety, Tolerability, and Hemodynamic Response of PB1046 in Subjects With PAH Pulmonary Arterial Hypertension | Phase 1 | 2017-10-20 |
| Completed | Study to Assess the Safety, Tolerability and PK/PD After 4 Weekly SC Injections of PB1046 in Subjects With Sta Heart Failure | Phase 2 | 2016-06-01 |
| Completed | Study to Assess the Safety, Tolerability, PK and PD Response of PE0139 Injection in Adult Subjects With T2DM Type 2 Diabetes Mellitus | Phase 2 | 2015-10-01 |
| Completed | Phase 1, Randomized, Double-Blind, Placebo-Controlled Exploratory Study That Will Assess the Safety, Tolerabil Essential Hypertension | Phase 1 | 2013-06-01 |
| Completed | Phase 1 Multicenter, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharm Type 2 Diabetes Mellitus (T2DM) | Phase 1 | 2013-04-01 |
| Completed | Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess Type 2 Diabetes Mellitus | Phase 2 | 2012-07-01 |
| Completed | Pharmacokinetic Profile of Two Formulations of PB1023 Following Single Subcutaneous Injection in Subjects With Diabetes Mellitus, Type 2 | Phase 1 | 2012-02-01 |
| Completed | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Response of Vasomera (PB1046) Injection Following Essential Hypertension | Phase 1 | 2012-01-01 |
| Completed | Pharmacokinetic, Safety/Tolerability Study of a Single SC Dose of PB1023 Injection in Subjects With Normal and Diabetes Mellitus, Type 2 | Phase 1 | 2011-12-01 |
| Completed | Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled, Study to Assess Safety, Tolerability, PK and PD Resp Diabetes Mellitus, Type 2 | Phase 1 / Phase 2 | 2010-11-01 |